Myriad Genetics 8-K 2011
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 08/15/2011
Myriad Genetics, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-26642
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On August 15, 2011, Myriad Genetics, Inc. (the Company) announced that its Board of Directors authorized the repurchase of $200 million of the Companys outstanding common stock. The Company plans to repurchase $200 million of shares of its common stock from time-to-time in open market purchases or privately negotiated purchases as determined by the companys management. The amount and timing of the stock repurchase will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. This repurchase program follows the completion of the Companys three previously authorized stock repurchase programs that totaled $300 million initiated in May 2010, August 2010, and March 2011.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.